Cadence Plans FDA Meeting To Discuss Mixed Trial Results For IV Acetaminophen
This article was originally published in The Pink Sheet Daily
Executive Summary
One of two Phase III trials for Acetavance met its primary endpoint, while a second missed its mark.
You may also be interested in...
Alpharma Ups Ante With Phase III Embeda Proof
Pain drug’s data could help lure more than King to the table.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.